Presentation is loading. Please wait.

Presentation is loading. Please wait.

The Organic Chemistry of Drug Design and Drug Action Chapter 2 Lead Discovery and Lead Modification.

Similar presentations

Presentation on theme: "The Organic Chemistry of Drug Design and Drug Action Chapter 2 Lead Discovery and Lead Modification."— Presentation transcript:

1 The Organic Chemistry of Drug Design and Drug Action Chapter 2 Lead Discovery and Lead Modification

2 Lead Discovery Approaches 1. Random screening - only approach before 1935; screen every compound you have; still a useful approach; streptomycin and tetracyclines identified in this way 2. Nonrandom (or Targeted or Focused) screening - only screen compounds related to active compounds 3. Drug metabolism studies - metabolites produced are screened for the same or other activities 4. Clinical observations - new activities found in clinical trials; Dramamine tested as antihistamine (allergy) - found to relieve motion sickness; Viagra tested as antihypertensive - found to treat erectile dysfunction

3 Lead Discovery Approaches (cont’d) 5. Rational approaches - identify causes for disease states: imbalance of chemicals in the body invasion of foreign organisms aberrant cell growth Identify biological systems involved in disease states; use natural receptor ligand or enzyme substrate as the lead; a known drug also can be used as a lead

4 Rational Drug Design Chemical imbalances - antagonism or agonism of a receptor; enzyme inhibition Foreign organism and aberrant cell growth - enzyme inhibition; DNA interaction

5 Dopamine as a lead compound FIGURE 2.1 Depiction of dopamine (DA) in its role as a neurotransmitter. DA is released by a neuron prior to interacting with dopamine receptors (D1–D5) on the surface of another nearby neuron. Also shown is the dopamine transporter, which terminates the action of dopamine by transporting the released neurotransmitter from the synaptic cleft back into the presynaptic neuron. Reprinted by permission from Macmillan Publishers Ltd: Nature Reviews Drug Discovery (Kreek, M. J.; LaForge, K. S.; Butelman, E. Pharmacotherapy of addictions. Nat. Rev. Drug Discov. 2002, 1, 710–726) Copyright 2002.

6 Leads based on neurotransmitters

7 Example of Rational Drug Design Serotonin, a mediator of inflammation, was used as the lead for the anti-inflammatory drug indomethacin. N H NH 2 HO indomethacin N CH 3 O OH CH 3 O Cl O

8 Steroid hormones as lead compounds

9 Peptide hormones as lead compounds

10 Transporter ligands as lead compounds

11 Enzyme substrates as lead compounds Physostigmine

12 Kinases as targets—ATP is the lead compound SCHEME 2.1 Reaction catalyzed by the kinase class of enzymes. Kinases catalyze the transfer of the terminal phosphate group of ATP or related molecules acceptor to the group of a substrate, in this case, an alcohol (ROH).

13 Other and repurposed ligands as lead compounds AIDS -> antihistamine Antihypertensive -> Parkinson’s Antidepressant -> back pain

14 Leads from screening

15 Sources of compounds for screening Natural products Collections of compounds High-throughput synthesis of a library of compounds Solid-phase synthesis Solution-phase synthesis

16 Natural product leads

17 Natural products seem to provide greater structural diversity than combinatorial chemistry. Natural products that are biologically active in assays generally have drug-like properties. Construction of chemical libraries based on natural product hits is a good compromise.

18 Solid-Phase Synthesis of a Natural Product-like Combinatorial Library Library based on the 2,2-dimethylbenzopyran scaffold, a privileged structure.

19 Solid-phase synthesis is used to make libraries of compounds SCHEME 2.2 Solid-phase synthesis of a library of 7-hydroxybenzodiazepines

20 Solid phase synthesis of a library SCHEME 2.3 Solid-phase synthesis of a library of 4-alkoxyproline derivatives

21 Combinatorial Chemistry Synthesis or biosynthesis of chemical libraries of molecules for lead discovery or lead modification Libraries prepared in a systematic and repetitive way by covalent assembly of building blocks to give diversity within a common scaffold. Synthesis carried out on a solid support (polymer resin). Isolation and purification of product of each step done by filtration and washing. Everything not attached to polymer is washed away, which allows use of excess reagents.

22 Alternatives: Carry out reactions in solution with excess reagents, which are scavenged with a polymer-bound scavenger. Filtration removes excess reagents bound to polymer. Or, use polymer-bound reagents. Main differences among various methods of combinatorial library synthesis: 1. Solid support used 2. Methods for assembling the building blocks 3. The state (immobilized or in solution) in which libraries are screened 4. Manner in which structures of active compounds are determined (encoding methods)

23 N = b x (Eq. 2.1) # synthetic steps # compounds in library # building blocks in each step If the # of building blocks varies in each step, then N = bcd... For example, consider a 4-step synthesis. If 25 different reactants (building blocks) are used in the first two steps, 20 in step three, and 15 in step four, there would be 25  25  20  15 = 187,500 different compounds (from only 85 different building blocks).

24 Peptide Libraries Split synthesis Also called mix and split or split and pool method Most common lead discovery approach for large libraries (10 4 - 10 6 compounds), assayed as library mixtures. Produces a collection of polymer beads, each containing one library member (100-500 pmol) A combinatorial library of all pentapeptides comprised of the 20 common amino acids: 20 5 = 3.2  10 6 peptides. For example, prepare a homogenous mixture of all tripeptides of His, Val, and Ser (3 3 = 27)

25 Split Synthesis of All Tripeptides Containing His, Val, and Ser

26 Split Synthesis of Most Active Hexapeptide for a  Opioid Receptor A combinatorial library is prepared of pentapeptides (comprised of the 20 main amino acids) bound to the MBHA polystyrene resin (makes peptide amides when cleaved off of resin) Assay the 20 combinatorial library mixtures (either still attached to bead or after cleavage) Set the N-terminal amino acid of most potent library constant Separate into 20 tubes, then add a different N-acetylamino acid to each tube

27 If the most potent was the library with Ac-Arg at N-terminus, Set all to Arg Vary 2nd amino acid Next 4 amino acids are a combinatorial library Determine best residue at 2nd position, then repeat process for 3rd position. Continue until you get most potent N-acetyl hexapeptide amide (in this case, AcArg-Phe-Met-Trp-Met-Thr-NH 2 ).

28 Problems with Split Synthesis Approach Most potent analog may be less potent than what was observed in a previous iteration Peptide-peptide interactions may have been responsible for previous potency (some peptides removed in next step) Active compound may be a complex of more than one peptide (some peptides removed in next step) Conformation may be different with fewer peptides present

29 Nonpeptide Libraries Problems with Assaying Multiple Compounds Together Many false negatives (active compound that does not produce a hit) and false positives (inactive compound that does produce a hit) observed. Therefore, single entity screens are used. Parallel synthesis - solid-phase reactions carried out to make individual compounds rapidly (and robotically) The library (50-10 4 compounds) is made in parallel without combining tubes so each support has one compound attached. The goal is to get as much molecular diversity with as much functionality as possible.

30 Solution phase synthesis of a library SCHEME 2.4 Solution-phase synthesis of a library of furanose derivatives

31 Libraries can be made in microtiter plates FIGURE 2.2 (A) Schematic of a typical 96-well microtiter plate. (Reprinted with permission from Custom Biogenic Systems ( (B) Picture of a 96-well microtiter plate taken by Jeffrey M. Vinocur, 4/21/06, published on Wikipedia Commons (

32 Libraries can be made in microtiter plates FIGURE 2.4 Image of 96-well filter plates. Reprinted with permission from Norgen Biotek Corp.

33 Polymer-bound scavenger reagents can be used in synthesis FIGURE 2.3 Product of polymer-bound N-methylglucosamine with borate anion

34 Another solid-phase scavenger SCHEME 2.5 Use of a solid-phase scavenger in solution-phase synthesis. In this example, a polymer-bound isocyanate is used to scavenge excess primary or secondary amine from a solution by forming the corresponding polymer-bound urea.

35 An antitumor drug discovered by combinatorial synthesis and high- throughput screening

36 Advantages and problems in high throughput synthesis Solid-phase synthesis can make large numbers of compounds, but purification is problematic and quantities are small. Solution-phase synthesis makes smaller numbers of compounds, but larger quantities and easier purification.

37 Properties that Influence Oral Bioavailability Lipinski’s Rule of 5 The “rule of 5” states that poor oral absorption and/or distribution are more likely when: The molecular weight is > 500 There are more than 5 H-bond donors (expressed as the sum of OH and NH groups) There are more than 10 H-bond acceptors (expressed as the sum of N and O atoms) The log P is > 5 It is highly likely (>90%) that compounds with two or more of these characteristics will have poor absorption properties. Antibiotics, antifungals, vitamins, and cardiac glycosides are the exception because they often have active transporters to carry them across membranes.

38 Alternative to Lipinski’s Rule of Five Veber and co-workers Poor oral bioavailability found as a result of increased molecular flexibility (independent of molecular weight), as measured by: greater than 10 rotatable bonds high polar surface area (> 140 Å 2 ) total hydrogen bond count (> a total of 12 donors and acceptors) Both the number of rotatable bonds and hydrogen bond count tend to increase with molecular weight, which may explain Lipinski’s first rule. Reduced polar surface area was found to correlate better with an increased permeation rate than did lipophilicity.

39 Privileged Structures and Drug-like Molecules Certain scaffolds are capable of binding to multiple receptor targets Appropriate structural modifications can change the activity Privileged structure benzodiazepines (a) Evans, B. E.; Rittle, K. E.; Bock, M. G.; DiPardo, R. M.; Freidinger, R. M.; Whitter, W. L.; Lundell, G. F.; Veber, D. F.; Anderson, P. S.; Chang, R. S. L.; Lotti, V. J.; Cerino, D. J.; Chen, T. B.; Kling, P. J.; Kunkel, K. A.; Springer, J. P.; Hirshfield, J. J. Med. Chem. 1988, 31, 2235. (b) Ariëns, E. J.; Beld, A. J.; Rodrigues de Miranda, J. F.; Simonis, A. M. in The Receptors: A Comprehensive Treatise; O'Brien, R. D., Ed.; Plenum Press: New York, 1979, p. 33. (b) Ariëns, E. J. Med. Res. Rev. 1987, 7, 367. (c) Patchett, A. A.; Nargund, R. P. Annu. Rep. Med. Chem. 2000, 35, 289. (d) Hajduk, P. J.; Bures, M.; Praestgaard, J.; Fesik, S. W. J. Med. Chem. 2000, 43, 3443. (e) Fecik, R. A.; Frank, K. E.; Gentry, E. J.; Menon, S. R.; Mitscher, L. A.; Telikepalli, Med. Res. Rev. 1998, 18, 149. (f) Horton, D. A.; Bourne, G. T.; Smythe, M. L. J. Computer-Aided Mol. Des. 2002, 16, 415. (g) Klabunde, T.; Hessler, B. Chembiochem. 2002, 3, 928. (h) Matter, H. Baringhaus, K.H.; Naumann, T.; Klabunde, T.; Pirard, B. Comb. Chem. High Throughput Screen. 2001, 4, 453. (i) Horton, D. A.; Bourne, G. T.; Smythe, M. L. Chem. Rev. 2003, 103, 893. N N O Y R NHCOR'

40 Drug-likeness Only 32 scaffolds describe half of all known drugs. 1 Average number of side chains per molecule is 4. If carbonyl is ignored, then 73% of the side chains in drugs are from top 20 most common side chains. 2 Drug-likeness may be an inherent property of some molecules. 3 Try these first. 1 Bemis, G. W.; Murcko, M. A. J. Med. Chem. 1996, 39, 2887. 2 Bemis, G. W.; Murcko, M. A. J. Med. Chem. 1999, 42, 5095. 3 Ajay; Walters, W. P.; Murcko, M. A. J. Med. Chem. 1998, 41, 3314.

41 Privileged structures FIGURE 2.5 Pairs of compounds containing a privileged structure (indole, dihydropyridine, or benzimidazole) and binding to diverse target classes

42 Some groups should be avoided because of possible toxicity

43 Sucralose is an alkyl halide, but was approved as a non-nutritive sweetener

44 Many nondrug-like molecules show up as active in screens - false positives. Appear to bind to numerous receptors, but not at the site of the natural ligand (called promiscuous drugs) May be the result of aggregate formation

45 SCHEME 2.6 The process of virtual screening to identify compounds that conform to a hypothesis specifying properties (that are discernible from a compound’s structure) that are required for activity Virtual screening can accelerate lead identification

46 Virtual screening databases are available Tripos LeadQuest Maybridge Accelrys ACD ZINC-a free database

47 Virtual screening process Identify substructure linked to desired activity Search database for molecules with active substructure 2D search just matches the structure 3D search can match molecular shape

48 FIGURE 2.6 Hypothetical example illustrating that substructure search (e.g., using pyridine as the search query) may not retrieve the most structurally similar compounds in a compound collection Substructure search problems

49 How to quantify similarity? T = N 11 /n-N 00 = 7/18-4 = 0.50

50 Computer-Based Methods of QSAR 3D-QSAR correlates diverse molecular structures and their biological function at a particular target. General approach assay a set of molecules align molecules according to some predetermined orientation rules calculate a set of spatially dependent parameters for each molecule determined in the receptor space derive a function relating each molecule’s spatial parameters to their biological property establish self-consistency and predictability of the function

51 Comparative Molecular Field Analysis (CoMFA) Molecule-receptor interactions are represented by steric and electrostatic fields exerted by each molecule A series of active compounds are identified and 3-D structural models constructed These structures are superimposed on one another and placed within a regular 3-D grid A probe atom placed at lattice points on grid where it is used to calculate steric and electrostatic potentials between itself and each superimposed structure A 3-D contour map is constructed to identify where lower or higher steric or electrostatic interactions increase binding

52 FIGURE 2.7 Example of a computer-generated pharmacophore model. From Laurini et al Bioorg. Med. Chem. Lett. 2010 (Ref. 111) A pharmacophore based on known ligands

53 Molecular Graphics Use of computers to display and manipulate molecular structures based on Fischer lock-and-key hypothesis. Structure-based drug design Computer-assisted drug design Computer-assisted molecular design Commercial software, such as Sybyl (Tripos), Insight II (Molecular Simulations), and Gold (Cambridge Crystallographic Data Center), are used. Need a high-resolution (crystal or solution) structure of a receptor with a ligand bound. The ligand can be removed graphically to expose the receptor binding site. Other molecules are docked into the binding site. synonymous names for the method

54 Haldol, a lead for HIV-1 protease inhibitors from docking

55 From “hit” to lead Screening results in hits In HTS, need to identify and confirm structure of hits In virtual screening, need to perform assays to confirm activity A series of analogs may be prepared Ligand efficiency = ΔG/N

56 Fragment-based identification of leads

57 Comparison of ligand and fragments 1 μM40 mM19 mM10 mM KiKi But structural studies show that the fragments do not bind in the same site

58 SAR by NMR NMR approach to identify and optimize high-affinity ligands bound to proteins Screen ~10 compounds at a time. Look for a 15 N-chemical shift in the protein NMR indicating compound bound at that amino acid in the protein. Once lead is identified, make a focused library of analogs to optimize lead. Screen a 2nd library to find one that binds to a site near to where the first compound bound. Optimize the 2nd lead. Link the two compounds together - binding affinity is dramatically increased. FIGURE 2.8 SAR by NMR methodology

59 Example of SAR by NMR Inhibition of stromelysin, a matrix metalloprotease (degrades extracellular matrix components in tissue remodeling and in arthritis, osteoporosis, and cancer) Site 1 Site 2Linker K d = 17 mM K d = 20  M K d = 17 nM Took 6 months to identify 2.45. Prior to this, no leads had been identified.

60 A clinical candidate from SAR by NMR

61 SAR by NMR What’s Really Involved? To see a 15 N chemical shift in NMR spectrum: 1. Overexpress protein in microorganism grown on 15 NH 4 Cl as sole N source to incorporate 15 N in all amino acids 2. Purify protein (need > 200 mg per spectrum) 3. Determine 3D structure of protein by various NMR techniques (mass < 40 kDa) If structure can be determined, SAR by NMR can screen 1000 compounds a day.

62 Generating a lead from fragments FIGURE 2.9 Ellman combinatorial methodology for lead generation with an unknown or impure protein

63 SAR by MS High-throughput mass spectrometry-based screen A set of diverse compounds screened by mass spectrometry to identify those that bind to a receptor Competition experiments determine compounds bound to different sites (ternary complex if bound to different sites; binary complex if at same site) For molecules bound to different sites, vary substituent size to determine which bind at adjacent sites Attach the two molecules with a linker

64 Substrate activity screening (SAS) FIGURE 2.10 Steps of SAS for identification of protease inhibitors

65 Linking fragments FIGURE 2.11 Three approaches to linking fragments: (A) fragment evolution, (B) fragment linking, and (C) fragment self-assembly. Reprinted with permission from Macmillan Publishers Ltd: Nature Reviews Drug Discovery (Reese, D. C.; Congreve, M.; Murray, C. W.; Carr, R. Fragment-based lead discovery. Nat. Rev. Drug Discov. 2004, 3, 660–672) Copyright 2004.

66 Fragment evolution FIGURE 2.12 Example of fragment-based lead discovery incorporating the fragment evolution approach followed by lead modification to an optimized compound. Ligand efficiencies help guide the overall process.

67 Fragment self-assembly—click chemistry FIGURE 2.13 Example of fragment-based lead discovery incorporating the fragment self-assembly approach: click chemistry

68 Leads for sleeping sickness FIGURE 2.14 (A) Structure of 2.51 complexed with 6-phosphogluconate dehydrogenase (6PGDH) determined by X-ray crystallography. (B) Structure of 2.53 complexed with 6PGDH predicted by computational docking. From Ruda, et al. Bioorg. Med. Chem. 2010, 18, 5056–5062.

69 Fragment-based development of a urokinase-type plasminogen activator inhibitor FIGURE 2.15 Progression from mexiletin (2.55, identified by fragment-based screening) to a potent orally bioavailable uPA

70 Lead Optimization Pharmacodynamics receptor interactions - structure of lead is similar to that of the natural receptor ligand or enzyme substrate PharmacokineticsADME - Absorption, Distribution, Metabolism, Excretion; depends on water solubility and lipid solubility Toxicity

71 Identification of the Active Part of the Lead First consider pharmacodynamics Pharmacophore - the relevant groups on the compound that interact with the receptor and produce activity Auxophore - the rest of the molecule

72 Some of the auxophoric groups interfere with binding of pharmacophoric groups and must be excised. Some of the auxophoric groups may neither bind to the receptor nor prevent the pharmacophoric groups from binding - these can be modified without effect on potency. Modification of these auxophoric groups may be used to correct ADME problems.

73 One approach to determine which are pharmacophoric atoms, which are auxophoric atoms hindering binding, and which are auxophoric atoms that can be modified is to cut away pieces of the lead and measure the effect on potency.

74 Example of Pharmacophore and Auxophore Identification Assume the well-known addictive analgesics below are the lead compounds. The darkened part is known to be the pharmacophore (you would not know that in a real- life example). All bind to the  opioid receptor What happens if we excise the bridging O (shown above not in the pharmacophore)?

75 3-4 times more potent than morphine Note: The structure is drawn to mimic that of morphine; it is not the lowest energy conformer. Maybe additional conformational flexibility allows the molecule to bind more effectively.

76 Next, remove half of the cyclohexene ring (also not in the pharmacophore). Less potent than morphine, but much lower addictive properties. about the same potency as morphine

77 Demerol 10-12% the potency of morphine Potency similar to morphine Removal of more rings

78 If every cut gives lower potency, either most of the molecule is in the pharmacophore or the cut causes a conformational change away from the bioactive conformation. Add groups to increase the pharmacophore. 3200 times more potent than morphine

79 Fentanyl and derivatives are the most potent opiates known. Is the ester group in carfentanil part of the pharmacophore?

80 Functional Group Modification Antibacterial agent carbutamide (2.64, R = NH 2 ) has an antidiabetic side effect. Replacement of NH 2 by CH 3 gives tolbutamide (2.64, R = CH 3 ), which is an antidiabetic drug with no antibacterial activity. An obvious relationship exists between molecular structure and its activity.

81 Antihypertensives Antihypertensive with diuretic activity Antihypertensive without diuretic activity

82 Structure-Activity Relationships (SARs) 1868 - Crum-Brown and Fraser Examined neuromuscular blocking effects of a variety of simple quaternary ammonium salts to determine if the quaternary amine in curare was the cause for its muscle paralytic properties. Conclusion: the physiological action is a function of chemical constitution

83 Curare alkaloid FIGURE 2.16 Structure of D -tubocurarine, a constituent of curare

84 Structurally specific drugs (most drugs): Act at specific sites (receptor or enzyme) Activity/potency susceptible to small changes in structure Structurally nonspecific drugs: No specific site of action Similar activities with varied structures (various gaseous anesthetics, sedatives, antiseptics)

85 Example of SAR Lead: sulfanilamide (R = H) Thousands of analogs synthesized From clinical trials, various analogs shown to possess three different activities: Antimicrobial Diuretic Antidiabetic

86 SAR General Structure of Antimicrobial Agents R = SO 2 NHR, SO 3 H Groups must be para Must be NH 2 (or converted to NH 2 in vivo) Replacement of benzene ring or added substituents decreases or abolishes activity R can be (but potency is reduced) R = SO 2 NR 2 gives inactive compounds

87 SAR Antidiabetic Agents X = O, S, or N

88 SAR Diuretics (2 types) hydrochlorothiazides R 2 is an electrophilic group high ceiling type (high level of diuresis)

89 SAR for Paclitaxel Paclitaxel (2.72, Taxol) - anticancer drug

90 structural drawing of a lead annotated to show where structural changes affect activity or potency Use of a molecular activity map- SAR Conclusions FIGURE 2.17

91 Structural Modifications Increase potency, therapeutic index and ADME Increase therapeutic index - measure of the ratio of the concentration of a drug that gives undesirable effects to that which gives desirable effects e.g., LD 50 (lethal dose for 50% of the test animals) ED 50 (effective dose to give maximum effect in 50% of test animals) Therefore, want LD 50 to be large and ED 50 to be small. The larger the therapeutic index, the greater the margin of safety. The more life threatening the disease, the lower is an acceptable therapeutic index.

92 Chlorambucil, an antitumor drug Therapeutic index = 23

93 Types of Structural Modifications Homologation - increasing compounds by a constant unit (e.g., CH 2 ) Effect of carbon chain length on drug potency Pharmacokinetic explanation: Increasing chain length increases lipophilicity and ability to cross membranes; if too high lipophilicity, it remains in the membrane Pharmacodynamic explanation: Hydrophobic pocket increases binding with increasing length; too large and does not fit into hydrophobic pocket Figure 2.18

94 in throat lozenges Branched chain groups are less lipophilic than straight chain groups.

95 Chain Branching Often lowers potency and/or changes activity; interferes with receptor binding More potent than the tertiary homolog

96 Phenothiazines 10-Aminoalkylphenothiazines (X = H) Promethazine-antispasmodic/antihistamine activities predominate Promazine-greatly reduced antispasmodic/antihistamine Activities, greatly enhanced sedative/tranquilizing activities Trimepazine-reduced tranquilizing activity enhanced antipruritic (anti-itch) activity All bind to different receptors

97 Bioisosterism Bioisosteres - substituents or groups with chemical or physical similarities that produce similar biological properties. Can attenuate toxicity, modify activity of lead, and/or alter pharmacokinetics of lead.

98 Classical Isosteres

99 Do not have the same number of atoms and do not fit steric and electronic rules of classical isosteres, but have similar biological activity. Non-Classical Isosteres


101 Examples of Bioisosteric Analogues

102 Changes in Activity by Bioisosterism If the S in phenothiazine neuroleptic drugs (2.75) is replaced by -CH=CH- or -CH 2 -CH 2 - bioisosteres, then dibenzazepine antidepressant drugs (2.76) result.

103 Changes resulting from bioisosteric replacements: Size, shape, electronic distribution, lipid solubility, water solubility, pK a, chemical reactivity, hydrogen bonding Effects of bioisosteric replacement: 1. Structural (size, shape, H-bonding are important) 2. Receptor interactions (all but lipid/H 2 O solubility are important) 3. Pharmacokinetics (lipophilicity, hydrophilicity, pK a, H-bonding are important) 4. Metabolism (chemical reactivity is important) Bioisosteric replacements allow you to tinker with whichever parameters are necessary to increase potency or reduce toxicity.

104 Bioisosterism allows modification of physicochemical parameters Multiple alterations may be necessary: If a bioisosteric modification for receptor binding decreases lipophilicity, you may have to modify a different part of the molecule with a lipophilic group. Where on the molecule do you go to make the modification? The auxophoric groups that do not interfere with binding.

105 Conformationally rigid analogs FIGURE 2.19 Conformationally rigid analogs to determine bioactive conformation

106 Ring-Chain Transformations Transformation of alkyl substituents into cyclic analogs, which generally does not affect potency. 2.80 and 2.81 have equivalent tranquilizing effects 2.82. and 2.83 have similar antipruritic activity 2.84 has better antiemetic activity than 2.80 Ring-chain transformation can have pharmacokinetic effects, such as increased lipophilicity or decreased metabolism.

107 Ring-chain transformations can affect toxicity toxicnontoxic

108 Peptidomimetics Peptides are important endogenous molecules - neurotransmitters, hormones, neuromodulators Peptide drugs - analgesics, antihypertensives, antitumor agents Peptides generally do not make good drug candidates rapidly proteolyzed in GI tract and serum poorly bioavailable rapidly excreted bind to multiple receptors Peptidomimetic - a compound that mimics or blocks the biological effect of a peptide, but without undesirable structural characteristics

109 Initially, retain conformational flexibility, but then refine to more conformationally-rigid analogs to hold groups in a bioactive conformation. Use the peptide as a lead - modify to minimize undesirable pharmacokinetic properties Try to mimic structure of the peptide when it is bound to the target receptor Replace as much of the peptide backbone as possible with nonpeptide fragments - leave the pharmacophoric groups

110 Captopril-inhibits angiotensin converting enzyme

111 Phenylalanine Peptidomimetics Increased lipophilicity and conformational rigidity - better absorption and poor recognition by proteases FIGURE 2.20 Conformationally restricted phenylalanine analogs

112 Conformationally-Restricted Peptides FIGURE 2.21 Conformationally restricted dipeptide analogs

113 Secondary Structure Mimetics -  -turns-  -helix  -loop  -strand FIGURE 2.22 Conformationally restricted secondary structure peptidomimetics

114 Scaffold Peptidomimetics Arg-Gly-Asp (RGD) common  -turn motif that binds to receptors FIGURE 2.23 RGD scaffold peptidomimetics

115 somatostatin agonistscaffold peptidomimetic

116 Thyrotropin-releasing hormone (TRH) A scaffold peptidomimetic for TRH

117 Peptide Backbone Isosteres Peptide amide bond replaced with alternative groups (statine)

118 Pseudopeptides

119 Mechanism of peptide hydrolysis FIGURE 2.24 Hydrolysis of a peptide bond showing the tetrahedral intermediate arising from nucleophilic attack of water on the carbonyl group of the peptide bond. The hydroxyethylene isostere analog is designed to mimic the tetrahedral intermediate.

120 Structure Modifications to Increase Oral Bioavailability ~ 75% of drug candidates do not go to clinical trials because of pharmacokinetic problems Less than 10% of drug candidates in clinical trials go to market ~ 40% of molecules that fail in clinical trials do so because of pharmacokinetic problems Therefore, examine pharmacokinetic problems, such as oral bioavailability and plasma half life, as early as possible in the drug discovery process.

121 Low water solubility (high lipophilicity) can be an important limiting factor for oral bioavailability. Highly lipophilic compounds are easily metabolized or bind to plasma proteins. Low lipophilicity leads to poor absorption (cannot cross membranes). Therefore, need to know lipophilicities of molecules and of substituents. Determination of lipophilicities of substituents by Corwin Hansch and co-workers is based on the Hammett equation for electronic effects.

122 Electronic Effects The Hammett Equation Hammett’s postulate: Electronic effects (both inductive and resonance) of a set of substituents should be similar for different organic reactions. Therefore, assign values for the electronic effect of different substituents in a standard organic reaction, then use these values to estimate rates in a new reaction.

123 Hammett Equation Standard system: benzoic acid derivatives Scheme 2.7 Equilibrium Constants As X becomes more e - -withdrawing, the reaction to the right should be favored (increased K a ).

124 Rate Constants Scheme 2.8 As X becomes more e - -withdrawing, rate should increase because of transition state stabilization (lower activation energy).

125 Linear Free-Energy Relationship Rates of hydrolysis of ethyl benzoates Dissociation constants of benzoic acids not for ortho substituents- steric/polar effects

126 k koko KoKo slope of line k o and K o are rate and equilibrium constants, respectively, for the parent compound (X = H) log  log K = K KoKo log koko k =  If is defined as , then Hammett equation Reaction constant (depends on reaction conditions) carbocation intermediate, - slope carbanion intermediate, + slope Electronic parameter (depends on electronic properties of substituent) the more e - -withdrawing, more + the more e - -donating, more - H = 0.0

127 Lipophilicity Effects: Hansch Equation Hansch thought there should be a linear free-energy relationship between lipophilicity and biological activity. 1. drug has to get to site of action (pharmacokinetics) 2. drug has to interact with site of action (pharmacodynamics) Action of drug depends on 2 processes:

128 Fluid Mosaic Model of Membrane Drug must pass through various membranes to reach the site of action Figure 2.26 lipid bilayer hydrophilic heads (OH, NH 3 +, sugars) lipophilic tails (steroid and hydrocarbon chains) Correlations noted earlier between lipid solubility and biological activity

129 Lipids found in membranes

130 Measured Lipophilicities Model for transport of drug to site of action Ability of compound to partition between 1-octanol (simulates membrane) and water (simulates cytoplasm) P = [compound] 1-octanol [compound] water (1-  ) (Eq. 2.7) degree of dissociation in H 2 O from ionization constants Measure of lipophilicity: partition coefficient (P) between 1-octanol and water:

131 Relative potency of drug (log ) 1 C concentration of drug that produces the biological effect log = -k(log P) 2 + k(log P) + k  1 C For a compound more soluble in H 2 O than in 1- octanol For a compound more soluble in 1-octanol than in H 2 O P < 1; log P is - P > 1; log P is + The larger the P, the more interaction of the drug with membranes (more lipophilic)

132 FIGURE 2.27 Effect of log P on biological response. P is the partition coefficient, and C is the oncentration of the compound required to produce a standard biological effect. Log P o is the optimal log P for biological activity. Parabolic Relationship Between Potency (log ) and log P 1 C optimum partition coefficient for biological activity log P 0 should be  2 to penentrate the CNS

133 Ionization of compounds leads to greater water solubility than predicted from the neutral structure. For compounds that can ionize (COO -, NH 3 +, etc.) use log D - log of distribution coefficient. Ionization is a function of pK a of a compound and pH of the medium; therefore, must specify pH. log D is the log P of an ionizable compound at a particular pH. log D 7.4 is the log P at pH 7.4

134 Effect of pH on log D fully protonated amine decreased concentration of protonated amine

135 Lipophilicity Substituent Constants  Derived the same as electronic substituent constants   = log P X - log P H = log PXPX PHPH log P for a compound with substituent X log P for a compound with no substituent

136  (like  ) is additive and constitutive Multiple substituents exert lipophilicity equal to the sum of individual substituents Effect depends on the molecule to which it is attached Alkyl groups are least constitutive  CH 3 ≈ 0.50 By definition,  H = 0 Therefore,  CH 2 =  CH 3



139 How does folding affect π values?

140 Log P = 2π CH3 + 2π CH2 + π CH=CH + 2logP PhOH -0.40 = 2(0.50)+2(0.50)+0.69+2(1.46)-0.40 =5.21 (experimental, 5.07)

141 Example of Additivity of  Constants Branching lowers log P or  by 0.2/branch branching log P 2.83 = 2  Ph +  CH +  OCH 2 +  CH 2 +  NMe 2 - 0.2  OCH 2 = log P CH 3 CH 2 OCH 2 CH 3 - 2  CH 3 -  CH 2 = 0.77 - 2(0.5) - 0.5 = -0.73  NMe 2 = log P Ph(CH 2 ) 3 NMe 2 -  Ph - 3  CH 2 = 2.68 - 2.13 - 3(0.5) = -0.95 log P 2.83 = 2(2.13) + 0.5 + (-0.73) + 0.5 + (-0.95) - 0.2 = 3.38 branching Experimental log P = 3.27

142 Computerization of Log P Values Several software packages are available to calculate log P. However, log P values can vary by 2 or more units among software packages.  values are constitutive - cannot account for all substituents on every scaffold. Measure log P for one member of a library, then see which software package comes closest to the experimental value.

143 Asp/Glu-COOH pK a 4 - 4.5 Cys-SH8.5 - 9 Tyr9.5 - 10 Ser/Thr-OH13.5 - 14 His6 - 6.5 Lys-NH 3 + 10 - 10.5 Arg12 - 13 Effects of Ionization on Lipophilicity and Oral Bioavailability Amino acid residues in receptors are ionized At physiological pH (pH 7.4) each is partially ionized and partially neutral. pH = pKa –log [HA]/[A-]

144 Ionization of a drug depends on pK a of groups and pH. Ionization has profound effect on lipophilicity (pharmacokinetics) and interaction with a receptor (pharmacodynamics). What if ionization of a drug is important for its binding to a receptor, but ionization may block its ability to cross membranes? Need to vary pK a to adjust equilibrium of ionized (bind to receptor) and neutral (cross membranes) form. Neutral form crosses membranes, then re-establishes equilibrium with ionized form on other side.

145 Ionized molecules that did not cross the membrane re-establish equilibrium with the neutral form, which can cross the membrane. Drug metabolism and excretion prevent continual re-establishment of equilibrium. The pK a of most alkaloids that act as neuroleptics, local anesthetics, and barbituates have values between 6 and 8. At neutral pH there is a mixture of neutral and cationic forms.

146 Aminacrine is more active at pH > 7

147 The uricosuric drug phenylbutazone has a pK a of 4.5 and is active as an anion. The pH of urine is ~ 4.8. Sulfinpyrazone (R=CH 2 CH 2 SOCH 3 )has a pK a of 2.8 Therefore all in anionic form. 20 times more potent than phenylbutazone SCHEME 2.10 Ionization equilibrium for phenylbutazone

148 Effect of ionization can be rationalized from pharmacokinetic or pharmacodynamic perspective. Pharmacokinetic - neutral form increases crossing of membranes Pharmacodynamic - neutral form binds in a hydrophobic pocket in receptor These can be differentiated using an isolated receptor (no membranes to cross so only pharmacodynamics) and whole cells or tissue (membranes to cross so pharmacokinetics and pharmacodynamics are important).

149 Pyrimethamine is absorbed as the neutral molecule, but active as the protonated ion

150 In a cell-free system (no membranes), the antibacterial activity of sulfamethoxazole is directly proportional to the degree of ionization (pharmacodynamics). In intact cells, where a drug must cross a membrane to get to the site of action, the antibacterial activity is proportional to its lipophilicity (neutral). SCHEME 2.11 Ionization equilibrium for sulfamethoxazole

151 Actual pK a Values pK a values depend on the microenvironment Molecular dynamics simulations indicate that the interior of proteins have dielectric constants about 2-3 (like benzene or dioxane); water has a high dielectric constant (78.5). COOH in a nonpolar environment - pK a higher because ionized form is destabilized. Asp-99 in 3-oxo-  5 -steroid isomerase is 9.5! Represents a change in equilibrium of 10 5 in favor of neutral form.

152 COOH that forms a salt bridge - pK a lower Multiple COOH groups adjacent - pK a higher to avoid adjacent anionic groups NH 2 in a nonpolar environment - pK a lower to avoid cationic form NH 2 in a salt bridge is stabilized - pK a higher Multiple basic groups adjacent - pK a lower to avoid adjacent cationic groups Lys amino group in acetoacetate decarboxylase has pK a 5.9 because adjacent residue is another Lys. Again about 10 5 change in equilibrium.

153 Such large changes in pK a in microenvironment indicate that lead modification also should involve large pK a variances. Determine in vitro and in vivo effects with pK a changes.


155 InactiveActive CNS drugs must cross the blood-brain barrier

156 Quantitative Structure-Activity Relationships 1868 - Crum-Brown and Fraser predict a mathematical relationship would be found between structure and activity 1962 - Corwin Hansch attempts to quantify effects of substituent modifications

157 QSAR Basis for quantitative drug design: Biological properties are a function of the physicochemical parameters, e.g., solubility, lipophilicity, electronic effects, ionization, stereochemistry, etc.  and  constants should be important considerations in lead modification. Steric factors also should be important for receptor binding.

158 Steric Effects: Taft Equation Taft defined a steric parameter E s Reference reaction: XCH 2 CO 2 Me XCH 2 CO 2 H + MeOH H3O+H3O+ E s (X = H) = 0 CH 3 E s = log k XCH 2 Me - log k CH 3 CO 2 Me = log k0k0 kXkX Hancock: E c s = E s =0.306(n-3) corrects for hyperconjugation

159 Correlation of Physicochemical Parameters (descriptors) with Biological Activity Hansch analysis Because there are at least two considerations for drug activity, lipophilicity (to get drug to the site of action) and electronic factors (at the site of action), Hansch derived: C 1 log = -k  2 + k  +  + k  potency regression coefficients Hansch Equation

160 Hansch equation generalized: log = -a  2 + b  +  + cE s + dS + e C 1 potency lipophilicity constant electronic constant steric constant other physico- chem. parameters Linear multiple regression analysis The best least-squares fit of the dependent variable (biological activity) to a linear combination of independent variables (descriptors) is determined.

161 Topliss Operational Schemes - Lead Optimization Nonmathematical, nonstatistical, noncomputerized use of Hansch principles. Consider benzenesulfonamide as lead (R = H) Vary  and  and determine effect on potency. This method requires an unfused benzene ring.

162 Topliss Decision Tree Because potency often increases with lipophilicity, first try a substituent with a +  value (e.g., Cl;  4-Cl = 0.71,  4-Cl = 0.23). Three possible outcomes - more potent (M), equipotent (E), or less potent (L) than parent. If more potent, can be because of + , + , or both. Hold one constant and vary other:  4-PhS = 2.32,  4-PhS = 0.18 would test lipophilicity  4-CF 3 = 0.88,  4- CF 3 = 0.54 would test electron withdrawal If 4-PhS compound is more potent than 4-Cl, increase lipophilicity more.

163 Topliss Decision Tree Figure 2.16

164 If 4-Cl analog is equipotent with parent, may be a counterbalance of favorable +  and unfavorable +  or vice versa. Try 4-Me  4-Me = 0.56,  4-Me = 0.17 or 4-NO 2  4- NO 2 = -0.28,  4- NO 2 = 0.78 If 4-Cl analog is less potent than parent, there may be a steric problem at C-4 or need -  and/or - . Try 3-Cl  3-Cl = 0.71,  3-Cl = 0.37

165 FIGURE 2.29 Craig plot of σ constants versus π values for aromatic substituents. This material is reproduced with the permission of John Wiley & Sons, Inc. From Craig, P. N. (1980) In "Burger’s Medicinal Chemistry," (M. E. Wolff, ed.), 4th ed., Part I, p. 343. Wiley, New York. Craig plot of σ and π values

166 Batch Selection Methods With Topliss operational scheme you need results from one compound before you know what to make next. Batchwise methods involve making a small group of preselected analogs and testing. Rank order the potencies, then compare with the rankings in Table 2.17. This table tells you which parameter is most important. E.g., if rank is 3,4-Cl 2 > 4-Cl > H > 4-Me > 4-OMe, then  is most important.

167 Then consult Table 2.18 for other substituents with that parameter. Cannot extend this method without computation.

168 Cluster Analysis Select one member from each cluster See which dominates

169 Donepezil was studied by QSAR

170 Free-Wilson approach to QSAR BA = Σ a i X i + μ a i = contribution of a to BA X i =1 or 0 μ = activity of parent skeleton R 1 = R 2 = R 3 = R 4 If R 5 is Cl or CH 3 and Cl > CH 3 Then assume Cl always better, regardless of other substituents

171 Scaffold hopping FIGURE 2.30 Example of scaffold hopping to identify new cholesterol-lowering statins from mevastatin

172 Scaffold hopping FIGURE 2.31 A variation of scaffold hopping that involves disconnection of bonds, rotation or flipping of the core, and reconnection of the pharmacophoric groups

173 Computer-Assisted Drug Design Discovery of the influenza drug zanamivir (Relenza TM ) A protein (hemagglutinin) at the surface of a virus binds to sialic acid residues on receptors at the host cell surface. The virus enters the cell and replicates in the nucleus. The virus has another protein (neuraminidase), which is an enzyme that cleaves sialic acid residues from the cell surface Sialic acidLead

174 Progeny virus particles escape the cell, which no longer has sialic acid residues on its surface to trap the virus. Inhibition of neuraminidase would prevent the release and spread of virus particles. The virus particles spread to other cells.

175 Random screen identified 2.129 (R = OH) as a weak inhibitor. From the crystal structure, extension of 4-ammonium with 4-guanidinium (2.93, zanamivir) would extend binding to Glu- 227 as well (Fig. 2.32). Crystal structure of influenza A neuraminidase with inhibitor bound was obtained. Computation (using GRID program) suggested 4-OH should be replaced by 4- NH 2, which when protonated would interact with Glu-119 (Fig 2.32). NH 3 + group group FIGURE 2.32 Crystal structure of neuraminidase active site with inhibitors bound. (A) Interaction of the protonated amino group of 2.129 (R = NH 3 + ) with Glu-119. (B) Interaction of the protonated guanidinium group of 2.127 with Glu-119 and (red arrow) Glu-227. Adapted with permission from Macmillan Publishers Ltd: Nature (von Itzstein, M., et al. Rational design of potent sialidase-based inhibitors of influence virus replication. Nature 1993, 363, 418–423) Copyright 1993.

176 Generally, drug discovery is not this easy - need a cyclic approach. Identify receptor binder Obtain crystal structure of receptor with molecule bound Do calculations and docking Synthesize new compounds Assay Obtain another crystal structure with more potent binder Repeat cycle

177 Computer modeling can be used to identify the pharmacophore. By overlaying the structure of the antitumor drug paclitaxel (2.72, Taxol) with those of 4 other natural products that also stabilize microtubules in competition with paclitaxel, (see next slide)

178 a common pharmacophore (Fig. 2.34, next slide) was identified. FIGURE 2.33 Five natural products found to promote stabilization of microtubules. The boxed sections were used to identify a common pharmacophore. With permission for I. Ojima (1999). Reprinted with permission from Proc. Natl. Acad. Sci. USA 1999, 96, 4256–4261. Copyright 1999 National Academy of Sciences, U.S.A.

179 A hybrid structure was then constructed (2.130). FIGURE 2.34 Common pharmacophore based on the composite of boxed sections in Figure 2.33. With permission for I. Ojima (1999). Reprinted with permission from Proc. Natl. Acad. Sci. USA 1999, 96, 4256–4261. Copyright 1999 National Academy of Sciences, U.S.A.

180 The design of a bryostatin analogue


Download ppt "The Organic Chemistry of Drug Design and Drug Action Chapter 2 Lead Discovery and Lead Modification."

Similar presentations

Ads by Google